niacin has been researched along with Arteriosclerosis, Coronary in 101 studies
Niacin: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.
vitamin B3 : Any member of a group of vitamers that belong to the chemical structural class called pyridines that exhibit biological activity against vitamin B3 deficiency. Vitamin B3 deficiency causes a condition known as pellagra whose symptoms include depression, dermatitis and diarrhea. The vitamers include nicotinic acid and nicotinamide (and their ionized and salt forms).
nicotinic acid : A pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the effect of extended release (ER) niacin on endothelial and vascular function assessed by brachial flow-mediated dilatation (FMD), peak hyperemic velocity (VTiRH) and pulse arterial tonometry (PAT) in patients with established coronary artery disease (CAD), already treated with high dose statins." | 9.17 | Niacin improves lipid profile but not endothelial function in patients with coronary artery disease on high dose statin therapy. ( Anderson, TJ; Hillard, D; Hubacek, J; Philpott, AC; Sun, YC, 2013) |
| "In this study, niacin was added to existing therapy for 3 months in 54 subjects with stable coronary artery disease." | 9.12 | Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease. ( Dave, DM; Karas, RH; Kimmelstiel, CD; Kuvin, JT; Mooney, P; Patel, AR; Sliney, KA, 2006) |
| " In our study, patients were randomized, on average, 6 days after an acute myocardial infarction and/or percutaneous transluminal coronary angioplasty secondary to unstable angina, to pravastatin (combined, when necessary, with cholestyramine and/or nicotinic acid) to achieve low-density lipoprotein cholesterol levels of < or =130 mg/dl (group A, n = 70)." | 9.09 | Beneficial effects of pravastatin (+/-colestyramine/niacin) initiated immediately after a coronary event (the randomized Lipid-Coronary Artery Disease [L-CAD] Study). ( Agrawal, R; Arntz, HR; Fischer, F; Schnitzer, L; Schultheiss, HP; Stern, R; Wunderlich, W, 2000) |
| " The AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) trial, which compared combined niacin/simvastatin with simvastatin alone, failed to demonstrate an incremental benefit of niacin among patients with atherosclerotic CVD and on-treatment low-density lipoprotein cholesterol values <70 mg/dl, but this study had some limitations." | 8.88 | Niacin and statin combination therapy for atherosclerosis regression and prevention of cardiovascular disease events: reconciling the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Ou ( Baer, JT; Blaha, MJ; Blumenthal, RS; Michos, ED; Sibley, CT, 2012) |
| "The change in logarithmic reactive hyperemia index between 1 month and 12 months was similar in patients receiving ER-niacin vs placebo (0." | 6.80 | Effect of Extended-Release Niacin on Carotid Intima Media Thickness, Reactive Hyperemia, and Endothelial Progenitor Cell Mobilization: Insights From the Atherosclerosis Lesion Progression Intervention Using Niacin Extended Release in Saphenous Vein Grafts ( Abdurrahim, G; Banerjee, S; Brilakis, ES; Chao, H; Christopoulos, G; Coleman, A; de Lemos, JA; Guerra, A; Han, H; Kotsia, A; McGuire, DK; Packer, M; Rangan, BV; Roesle, M; Sosa, A; Xu, H, 2015) |
| "Niacin treatment was without effect on FMD or NMD, respectively, compared to placebo." | 6.74 | Effects of oral niacin on endothelial dysfunction in patients with coronary artery disease: results of the randomized, double-blind, placebo-controlled INEF study. ( Blankenberg, S; Elsner, V; Lackner, K; Munzel, T; Ostad, MA; Peetz, D; Schinzel, R; Stieber, F; Walter, U; Warnholtz, A; Wild, P, 2009) |
| " How safe and well-tolerated is this combination? One hundred sixty patients with CAD, including 25 with diabetes mellitus, with mean low-density lipoprotein cholesterol of 128 mg/dl, HDL cholesterol of < or =35 mg/dl (mean 31), and mean triglycerides of 217 mg/dl were randomized to 4 factorial combinations of antioxidant vitamins or their placebos and simvastatin plus niacin or their placebos." | 6.71 | Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study). ( Albers, JJ; Brown, BG; Chait, A; DeAngelis, D; Dowdy, AA; Frohlich, J; Heise, N; Morse, JS; Zhao, XQ, 2004) |
| "To determine the effect of extended release (ER) niacin on endothelial and vascular function assessed by brachial flow-mediated dilatation (FMD), peak hyperemic velocity (VTiRH) and pulse arterial tonometry (PAT) in patients with established coronary artery disease (CAD), already treated with high dose statins." | 5.17 | Niacin improves lipid profile but not endothelial function in patients with coronary artery disease on high dose statin therapy. ( Anderson, TJ; Hillard, D; Hubacek, J; Philpott, AC; Sun, YC, 2013) |
| "To assess effects of niacin on risk factors of atherosclerosis in men with coronary heart disease (CHD) and high lipoprotein(a) [Lp(a)] levels." | 5.15 | [Pleiotropic effects of nicotinic acid therapy in men with coronary heart disease and elevated lipoprotein(a) levels]. ( Afanas'eva, MI; Afanas'eva, OI; Ezhov, MV; Liakishev, AA; Pokrovskiĭ, SN; Safarova, MS; Tripoten', MI; Trukhacheva, EP, 2011) |
| " This study aimed to investigate the effects of combined application of extended-release niacin and atorvastatin on lipid profile modification and the risks of adverse events in patients with coronary artery disease." | 5.14 | Combined use of extended-release niacin and atorvastatin: safety and effects on lipid modification. ( Chen, SY; Li, YG; Li, YH; Sang, ZC; Wang, F; Wang, HP; Zhou, Q, 2009) |
| "In this study, niacin was added to existing therapy for 3 months in 54 subjects with stable coronary artery disease." | 5.12 | Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease. ( Dave, DM; Karas, RH; Kimmelstiel, CD; Kuvin, JT; Mooney, P; Patel, AR; Sliney, KA, 2006) |
| "The HDL Atherosclerosis Treatment Study (HATS) demonstrated a clinical benefit in coronary artery disease patients with low HDL cholesterol (HDL-C) levels treated with simvastatin and niacin (S-N) or S-N plus antioxidants (S-N+A) compared with antioxidants alone or placebo." | 5.10 | Impact of simvastatin, niacin, and/or antioxidants on cholesterol metabolism in CAD patients with low HDL. ( Brown, BG; Giovanni, A; Lichtenstein, AH; Matthan, NR; Schaefer, EJ, 2003) |
| " In our study, patients were randomized, on average, 6 days after an acute myocardial infarction and/or percutaneous transluminal coronary angioplasty secondary to unstable angina, to pravastatin (combined, when necessary, with cholestyramine and/or nicotinic acid) to achieve low-density lipoprotein cholesterol levels of < or =130 mg/dl (group A, n = 70)." | 5.09 | Beneficial effects of pravastatin (+/-colestyramine/niacin) initiated immediately after a coronary event (the randomized Lipid-Coronary Artery Disease [L-CAD] Study). ( Agrawal, R; Arntz, HR; Fischer, F; Schnitzer, L; Schultheiss, HP; Stern, R; Wunderlich, W, 2000) |
| " The AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) trial, which compared combined niacin/simvastatin with simvastatin alone, failed to demonstrate an incremental benefit of niacin among patients with atherosclerotic CVD and on-treatment low-density lipoprotein cholesterol values <70 mg/dl, but this study had some limitations." | 4.88 | Niacin and statin combination therapy for atherosclerosis regression and prevention of cardiovascular disease events: reconciling the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Ou ( Baer, JT; Blaha, MJ; Blumenthal, RS; Michos, ED; Sibley, CT, 2012) |
| "Combined statin and niacin therapy partially reverses the changes in the protein composition seen in HDL(3) in coronary artery disease subjects." | 3.74 | Combined statin and niacin therapy remodels the high-density lipoprotein proteome. ( Brunzell, J; Green, PS; Heinecke, JW; Knopp, RH; Kulstad, JJ; Marcovina, S; Moore, AB; Pennathur, S; Vaisar, T; Zhao, XQ, 2008) |
| "This report describes a patient with coronary artery disease who was instructed to take extended-release niacin to treat low high-density lipoprotein cholesterol and instead purchased "flush-free niacin" available at the pharmacy." | 3.73 | "Flush-free niacin": dietary supplement may be "benefit-free". ( Norris, RB, 2006) |
| "The change in logarithmic reactive hyperemia index between 1 month and 12 months was similar in patients receiving ER-niacin vs placebo (0." | 2.80 | Effect of Extended-Release Niacin on Carotid Intima Media Thickness, Reactive Hyperemia, and Endothelial Progenitor Cell Mobilization: Insights From the Atherosclerosis Lesion Progression Intervention Using Niacin Extended Release in Saphenous Vein Grafts ( Abdurrahim, G; Banerjee, S; Brilakis, ES; Chao, H; Christopoulos, G; Coleman, A; de Lemos, JA; Guerra, A; Han, H; Kotsia, A; McGuire, DK; Packer, M; Rangan, BV; Roesle, M; Sosa, A; Xu, H, 2015) |
| "Niacin treatment was without effect on FMD or NMD, respectively, compared to placebo." | 2.74 | Effects of oral niacin on endothelial dysfunction in patients with coronary artery disease: results of the randomized, double-blind, placebo-controlled INEF study. ( Blankenberg, S; Elsner, V; Lackner, K; Munzel, T; Ostad, MA; Peetz, D; Schinzel, R; Stieber, F; Walter, U; Warnholtz, A; Wild, P, 2009) |
| " How safe and well-tolerated is this combination? One hundred sixty patients with CAD, including 25 with diabetes mellitus, with mean low-density lipoprotein cholesterol of 128 mg/dl, HDL cholesterol of < or =35 mg/dl (mean 31), and mean triglycerides of 217 mg/dl were randomized to 4 factorial combinations of antioxidant vitamins or their placebos and simvastatin plus niacin or their placebos." | 2.71 | Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study). ( Albers, JJ; Brown, BG; Chait, A; DeAngelis, D; Dowdy, AA; Frohlich, J; Heise, N; Morse, JS; Zhao, XQ, 2004) |
| "Progression of coronary artery disease is assumed to be a surrogate end point for clinical coronary events." | 2.68 | Progression of coronary artery disease predicts clinical coronary events. Long-term follow-up from the Cholesterol Lowering Atherosclerosis Study. ( Azen, SP; Blankenhorn, DH; Cashin-Hemphill, L; Hodis, HN; LaBree, L; Mack, WJ; Selzer, RH; Shircore, AM, 1996) |
| "Lipid-lowering therapy ameliorates coronary atherosclerosis in patients with raised concentrations of low-density-lipoprotein (LDL) cholesterol." | 2.67 | Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients. Harvard Atherosclerosis Reversibility Project (HARP) Group. ( Gibson, CM; Pasternak, RC; Rosner, B; Sacks, FM; Stone, PH, 1994) |
| "Niacin has a favorable unique impact on factors affecting the rate of glomerular filtration rate decline, including high-density lipoprotein (HDL) particle number and function, triglyceride levels, oxidant stress, inflammation and endothelial function, and lowering of serum phosphorus levels by reducing dietary phosphorus absorption in the gastrointestinal tract." | 2.52 | Niacin and progression of CKD. ( Kalantar-Zadeh, K; Kashyap, ML; Kovesdy, CP; Moradi, H; Streja, DA; Streja, E, 2015) |
| "Niacin treatment reduces cardiovascular events and the progression of atherosclerosis." | 2.45 | Nicotinic acid and the prevention of coronary artery disease. ( Choudhury, RP; Digby, JE; Lee, JM, 2009) |
| "As the significance of treating coronary artery disease (CAD) remains a high priority in reducing morbidity and mortality worldwide, newer treatment strategies continue to evolve." | 2.45 | Novel targets that affect high-density lipoprotein metabolism: the next frontier. ( Davidson, MH; Rosenson, RS, 2009) |
| "Furthermore, severe hypertriglyceridemia is associated with an increased risk of acute pancreatitis, irrespective of its effect on risk of cardiovascular disease." | 2.44 | Hypertriglyceridemia: its etiology, effects and treatment. ( Al-Shali, KZ; Hegele, RA; Yuan, G, 2007) |
| "Niacin has been shown to regress atherosclerosis when used as monotherapy, in combination with a statin, and in combination with nonstatin therapies (including cholesterol-binding resins) and fibrates." | 2.44 | Evidence to support aggressive management of high-density lipoprotein cholesterol: implications of recent imaging trials. ( Taylor, AJ, 2008) |
| "The metabolic syndrome and type 2 diabetes mellitus are both becoming more prevalent, and both increase the risk of cardiovascular disease." | 2.43 | Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome. ( Nesto, RW, 2005) |
| "Hypertriglyceridemia is commonly embedded in the context of a metabolic syndrome that includes central obesity, insulin resistance, low levels of HDL cholesterol, and often hypertension." | 2.41 | A risk factor for atherosclerosis: triglyceride-rich lipoproteins. ( Kane, JP; Malloy, MJ, 2001) |
| "Treatment of dyslipidemia to prevent CHD depends on the pattern and severity of dyslipidemia, the presence of overt CHD, and the patient's response to diet." | 2.40 | Perspectives in the treatment of dyslipidemias in the prevention of coronary heart disease. ( Borgia, MC; Medici, F, 1998) |
| " Third, lower levels of HDL cholesterol are associated in a dose-response fashion with the severity and number of angiographically documented atherosclerotic coronary arteries." | 2.40 | The antiatherogenic role of high-density lipoprotein cholesterol. ( Kwiterovich, PO, 1998) |
| "Niacin has been studied in 6 major clinical trials with cardiovascular endpoints." | 2.40 | Effect of niacin on atherosclerotic cardiovascular disease. ( Guyton, JR, 1998) |
| "Dyslipidemia is one of the risk factors for the development of coronary atherosclerosis." | 2.39 | Number-needed-to-treat analysis of the prevention of myocardial infarction and death by antidyslipidemic therapy. ( Rembold, CM, 1996) |
| "Ten patients with NIDDM, CAD, and severe LV dysfunction (mean ejection fraction, 29." | 1.31 | Myocardial glucose utilization and optimization of (18)F-FDG PET imaging in patients with non-insulin-dependent diabetes mellitus, coronary artery disease, and left ventricular dysfunction. ( Beanlands, RS; deKemp, RA; Ruddy, TD; Vitale, GD; Williams, K, 2001) |
| "13 patients aged 39 to 60 years with coronary atherosclerosis confirmed at selective coronary angiography combined with primary hyperlipidemia (phenotypes 2a and 2b) received enduracin in a dose 1500 mg/day." | 1.30 | [The effect of long-term Enduracin monotherapy on the clinical and biochemical status of patients with ischemic heart disease]. ( Aronskaia, EE; Kukharchuk, VV; Malyshev, PP; Rozhkova, TA; Semenova, OA; Solov'ev, EIu, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (8.91) | 18.7374 |
| 1990's | 21 (20.79) | 18.2507 |
| 2000's | 47 (46.53) | 29.6817 |
| 2010's | 24 (23.76) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pisarik, P | 1 |
| Ponce, OJ | 1 |
| Larrea-Mantilla, L | 1 |
| Hemmingsen, B | 1 |
| Serrano, V | 1 |
| Rodriguez-Gutierrez, R | 1 |
| Spencer-Bonilla, G | 1 |
| Alvarez-Villalobos, N | 1 |
| Benkhadra, K | 1 |
| Haddad, A | 1 |
| Gionfriddo, MR | 1 |
| Prokop, LJ | 1 |
| Brito, JP | 1 |
| Murad, MH | 1 |
| Egom, EE | 1 |
| Mamas, MA | 1 |
| Soran, H | 1 |
| Ylä-Herttuala, S | 1 |
| Bentzon, JF | 1 |
| Daemen, M | 1 |
| Falk, E | 1 |
| Garcia-Garcia, HM | 1 |
| Herrmann, J | 1 |
| Hoefer, I | 1 |
| Jauhiainen, S | 1 |
| Jukema, JW | 1 |
| Krams, R | 1 |
| Kwak, BR | 1 |
| Marx, N | 1 |
| Naruszewicz, M | 1 |
| Newby, A | 1 |
| Pasterkamp, G | 1 |
| Serruys, PW | 1 |
| Waltenberger, J | 1 |
| Weber, C | 1 |
| Tokgözoglu, L | 1 |
| Gudzune, KA | 1 |
| Monroe, AK | 1 |
| Sharma, R | 1 |
| Ranasinghe, PD | 1 |
| Chelladurai, Y | 1 |
| Robinson, KA | 1 |
| Streja, E | 1 |
| Kovesdy, CP | 1 |
| Streja, DA | 1 |
| Moradi, H | 1 |
| Kalantar-Zadeh, K | 1 |
| Kashyap, ML | 1 |
| Guerra, A | 1 |
| Rangan, BV | 1 |
| Coleman, A | 1 |
| Xu, H | 1 |
| Kotsia, A | 1 |
| Christopoulos, G | 1 |
| Sosa, A | 1 |
| Chao, H | 1 |
| Han, H | 1 |
| Abdurrahim, G | 1 |
| Roesle, M | 1 |
| de Lemos, JA | 1 |
| McGuire, DK | 1 |
| Packer, M | 1 |
| Banerjee, S | 1 |
| Brilakis, ES | 1 |
| Vavlukis, M | 1 |
| Mladenovska, K | 1 |
| Daka, A | 1 |
| Dimovski, A | 1 |
| Domazetovska, S | 1 |
| Kuzmanovska, S | 1 |
| Kedev, S | 1 |
| Albers, JJ | 2 |
| Slee, A | 1 |
| Fleg, JL | 1 |
| O'Brien, KD | 1 |
| Marcovina, SM | 1 |
| Rembold, CM | 3 |
| Green, PS | 1 |
| Vaisar, T | 1 |
| Pennathur, S | 1 |
| Kulstad, JJ | 1 |
| Moore, AB | 1 |
| Marcovina, S | 1 |
| Brunzell, J | 1 |
| Knopp, RH | 1 |
| Zhao, XQ | 3 |
| Heinecke, JW | 1 |
| Warnholtz, A | 1 |
| Wild, P | 1 |
| Ostad, MA | 1 |
| Elsner, V | 1 |
| Stieber, F | 1 |
| Schinzel, R | 1 |
| Walter, U | 1 |
| Peetz, D | 1 |
| Lackner, K | 1 |
| Blankenberg, S | 1 |
| Munzel, T | 1 |
| Robinson, JG | 1 |
| Cooper-DeHoff, RM | 1 |
| Pacanowski, MA | 1 |
| Pepine, CJ | 1 |
| Digby, JE | 1 |
| Lee, JM | 1 |
| Choudhury, RP | 1 |
| Sang, ZC | 1 |
| Wang, F | 1 |
| Zhou, Q | 1 |
| Li, YH | 1 |
| Li, YG | 1 |
| Wang, HP | 1 |
| Chen, SY | 1 |
| Davidson, MH | 5 |
| Rosenson, RS | 1 |
| Riesen, WF | 1 |
| Duggal, JK | 1 |
| Singh, M | 1 |
| Attri, N | 1 |
| Singh, PP | 1 |
| Ahmed, N | 1 |
| Pahwa, S | 1 |
| Molnar, J | 1 |
| Singh, S | 1 |
| Khosla, S | 1 |
| Arora, R | 1 |
| Natarajan, P | 1 |
| Ray, KK | 1 |
| Cannon, CP | 1 |
| Devendra, GP | 1 |
| Whitney, EJ | 1 |
| Krasuski, RA | 2 |
| Johansen, CT | 1 |
| Kathiresan, S | 1 |
| Hegele, RA | 2 |
| Safarova, MS | 1 |
| Trukhacheva, EP | 1 |
| Ezhov, MV | 1 |
| Afanas'eva, OI | 1 |
| Afanas'eva, MI | 1 |
| Tripoten', MI | 1 |
| Liakishev, AA | 1 |
| Pokrovskiĭ, SN | 1 |
| Custodis, F | 1 |
| Laufs, U | 1 |
| Elmallah, W | 1 |
| Nicholls, SJ | 1 |
| Michos, ED | 1 |
| Sibley, CT | 1 |
| Baer, JT | 1 |
| Blaha, MJ | 1 |
| Blumenthal, RS | 1 |
| Yeboah, J | 1 |
| Philpott, AC | 1 |
| Hubacek, J | 1 |
| Sun, YC | 1 |
| Hillard, D | 1 |
| Anderson, TJ | 1 |
| Matthan, NR | 1 |
| Giovanni, A | 1 |
| Schaefer, EJ | 1 |
| Brown, BG | 5 |
| Lichtenstein, AH | 1 |
| Hecht, HS | 2 |
| Harman, SM | 2 |
| Ryan, MJ | 1 |
| Gibson, J | 1 |
| Simmons, P | 1 |
| Stanek, E | 1 |
| Ito, MK | 1 |
| GOLDSBOROUGH, CE | 1 |
| POPA, Iu | 1 |
| ILIESCU, M | 1 |
| DOMOCOS, G | 1 |
| IACOBINI, P | 1 |
| CONSTANTINESCU, S | 1 |
| ILIESCU, CC | 1 |
| BUEDINGEN, F | 1 |
| MOELLER, HC | 1 |
| Wang, M | 1 |
| Briggs, MR | 1 |
| Morse, JS | 1 |
| Dowdy, AA | 1 |
| Heise, N | 2 |
| DeAngelis, D | 2 |
| Frohlich, J | 2 |
| Chait, A | 2 |
| VINOGRADOV, AV | 1 |
| Ng, DS | 1 |
| Wierzbicki, AS | 1 |
| Reasner, CA | 1 |
| McKenney, JM | 1 |
| Nesto, RW | 1 |
| Schwiesow, SJ | 1 |
| Nappi, JM | 1 |
| Ragucci, KR | 1 |
| Norris, RB | 1 |
| Vogt, A | 1 |
| Kassner, U | 1 |
| Hostalek, U | 1 |
| Peiter, A | 1 |
| Steinhagen-Thiessen, E | 1 |
| Kuvin, JT | 2 |
| Dave, DM | 1 |
| Sliney, KA | 1 |
| Mooney, P | 1 |
| Patel, AR | 2 |
| Kimmelstiel, CD | 1 |
| Karas, RH | 2 |
| Yuan, G | 1 |
| Al-Shali, KZ | 1 |
| Yavasoglu, I | 1 |
| Kadikoylu, G | 1 |
| Bolaman, Z | 1 |
| Röggla, G | 1 |
| Fasan, M | 1 |
| Kapiotis, S | 1 |
| Holub, BJ | 1 |
| Toth, PP | 1 |
| Ballantyne, CM | 1 |
| Polonsky, TS | 1 |
| Taylor, AJ | 1 |
| Leithäuser, B | 1 |
| Gerk, U | 1 |
| Mrowietz, C | 1 |
| Jung, F | 1 |
| Park, JW | 1 |
| Lapuerta, P | 1 |
| Azen, SP | 7 |
| LaBree, L | 3 |
| Sacks, FM | 1 |
| Pasternak, RC | 1 |
| Gibson, CM | 1 |
| Rosner, B | 1 |
| Stone, PH | 1 |
| Bays, H | 1 |
| Dujovne, CA | 1 |
| Mays, JB | 1 |
| Mack, WJ | 6 |
| Cashin-Hemphill, L | 3 |
| Shircore, AM | 3 |
| Selzer, RH | 5 |
| Blankenhorn, DH | 6 |
| Hodis, HN | 3 |
| Kukharchuk, VV | 1 |
| Solov'ev, EIu | 1 |
| Malyshev, PP | 1 |
| Rozhkova, TA | 1 |
| Semenova, OA | 1 |
| Aronskaia, EE | 1 |
| Borgia, MC | 1 |
| Medici, F | 1 |
| Cheung, M | 1 |
| Dowdy, A | 1 |
| Fisher, LD | 1 |
| Albers, J | 1 |
| Kwiterovich, PO | 1 |
| Guyton, JR | 1 |
| Zambon, A | 1 |
| Hokanson, JE | 1 |
| Brunzell, JD | 1 |
| Xiang, M | 1 |
| Liu, C | 1 |
| Arntz, HR | 1 |
| Agrawal, R | 1 |
| Wunderlich, W | 1 |
| Schnitzer, L | 1 |
| Stern, R | 1 |
| Fischer, F | 1 |
| Schultheiss, HP | 1 |
| Kris-Etherton, PM | 1 |
| Vitale, GD | 1 |
| deKemp, RA | 1 |
| Ruddy, TD | 1 |
| Williams, K | 1 |
| Beanlands, RS | 1 |
| SoRelle, R | 1 |
| Malloy, MJ | 2 |
| Kane, JP | 2 |
| Klungel, OH | 1 |
| Heckbert, SR | 1 |
| de Boer, A | 1 |
| Leufkens, HG | 1 |
| Sullivan, SD | 1 |
| Fishman, PA | 1 |
| Veenstra, DL | 1 |
| Psaty, BM | 1 |
| Drown, DJ | 1 |
| Dalessandri, KM | 1 |
| Rämet, ME | 1 |
| Pandian, NG | 1 |
| Mendelsohn, ME | 1 |
| Squires, RW | 1 |
| Allison, TG | 1 |
| Gau, GT | 1 |
| Miller, TD | 1 |
| Kottke, BA | 1 |
| Crawford, DW | 1 |
| Pogoda, J | 1 |
| Lee, PL | 2 |
| Pogoda, JM | 2 |
| Szamosi, A | 1 |
| Shepherd, J | 1 |
| Simpson, H | 1 |
| Williamson, CM | 1 |
| Pringle, S | 1 |
| MacLean, J | 1 |
| Lorimer, AR | 1 |
| Packard, CJ | 1 |
| Johansson, J | 1 |
| Carlson, LA | 1 |
| Ports, TA | 1 |
| Phillips, NR | 1 |
| Diehl, JC | 1 |
| Havel, RJ | 1 |
| Sanmarco, ME | 2 |
| Alaupovic, P | 1 |
| Wickham, E | 1 |
| Chin, HP | 1 |
| Witztum, JL | 1 |
| Nessim, SA | 1 |
| Johnson, RL | 1 |
| Tseluĭko, VI | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Extended-Release Niacin on Saphenous Vein Graft Atherosclerosis: The Atherosclerosis Lesion Progression Intervention Using Niacin Extended Release in Saphenous Vein Grafts (ALPINE-SVG) Pilot Trial[NCT01221402] | Phase 2 | 38 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| Carotid Plaque Composition by Magnetic Resonance Imaging During Lipid Lowering Therapy[NCT00715273] | Phase 4 | 217 participants (Actual) | Interventional | 2001-05-01 | Completed | ||
| FLAT-SUGAR: FLuctuATion Reduction With inSULin and Glp-1 Added togetheR[NCT01524705] | Phase 4 | 102 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
| AIM HIGH: Niacin Plus Statin to Prevent Vascular Events[NCT00120289] | Phase 3 | 3,414 participants (Actual) | Interventional | 2005-09-30 | Terminated (stopped due to AIM-HIGH was stopped on the recommendation of the DSMB because of lack of efficacy of niacin in preventing primary outcome events.) | ||
| Role of Lipoprotein(a) Concentration and Apolipoprotein(a) Phenotype in Prediction of Coronary Events in General Population[NCT02515747] | 1,400 participants (Actual) | Interventional | 1993-01-31 | Completed | |||
| HDL Modulation and Endothelial Function[NCT00150722] | Phase 3 | 75 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| [NCT00000461] | Phase 2 | 0 participants | Interventional | 1986-12-31 | Completed | ||
| [NCT00000599] | Phase 3 | 0 participants | Interventional | 1980-06-30 | Completed | ||
| ARBITER 6: ARterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6 - HDL and LDL Treatment Strategies in Atherosclerosis (HALTS)[NCT00397657] | Phase 4 | 400 participants (Anticipated) | Interventional | 2006-11-30 | Terminated (stopped due to Independent steering committee has stopped the trial based on results of a prespecified, blinded interim analysis. It was not stopped due to safety concerns.) | ||
| [NCT00005696] | 0 participants | Observational | 1994-01-31 | Completed | |||
| [NCT00000553] | Phase 3 | 0 participants | Interventional | 1994-09-30 | Completed | ||
| Niacin Therapy to Improve Endothelial Function in Sickle Cell Disease[NCT00508989] | Phase 2 | 30 participants (Actual) | Interventional | 2007-07-24 | Completed | ||
| Human Lipoprotein Pathophysiology - Subproject: Genetics of Familial Combined Hyperlipidemia[NCT00005313] | 450 participants (Actual) | Observational | 2001-04-30 | Completed | |||
| Familial Atherosclerosis Treatment Study[NCT00000512] | Phase 3 | 146 participants (Actual) | Interventional | 1984-01-31 | Completed | ||
| Correlates of Angiographic Changes and Coronary Events: The Cholesterol-Lowering Atherosclerosis Study (CLAS)[NCT00005433] | 188 participants (Actual) | Observational | 1996-04-30 | Completed | |||
| Lipoprotein Metabolism in Normal Volunteers and Dyslipoproteinemic Patients (Stable Isotopes)[NCT00001226] | 90 participants | Observational | 1987-12-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The primary endpoint of this study is carotid plaque lipid composition identified by MRI. The determination of plaque lipid content for each carotid artery will be performed using the automated interactive system. These measurements will be performed from the MRI scans at four time points blinded to time sequence of MRI examinations, patient treatment, lipid levels and clinical course.~Volume Measurements: Contours were placed around the lumen, outer-wall boundaries, and plaque features of carotid artery. (Arterial wall area) = (outer-wall area) - (lumen area). Volume calculated as: area x 2 mm (slice thickness). Tissue volume/wall volume x (100%) is presented as percentage. Annualized change presented mm^3/year (for volume) and as percentage change/year." (NCT00715273)
Timeframe: Measured at Years 1, 2, and 3
| Intervention | mm^3/year (Mean) |
|---|---|
| 1 - Single Therapy Group | -4.6 |
| 2 - Double Therapy Group | -15.1 |
| 3 - Triple Therapy Group | -9.4 |
"The primary endpoint of this study is carotid plaque lipid composition identified by MRI. The determination of plaque lipid content for each carotid artery will be performed using the automated interactive system. These measurements will be performed from the MRI scans at four time points blinded to time sequence of MRI examinations, patient treatment, lipid levels and clinical course.~Volume Measurements: Contours were placed around the lumen, outer-wall boundaries, and plaque features of carotid artery. (Arterial wall area) = (outer-wall area) - (lumen area). Volume calculated as: area x 2 mm (slice thickness). Tissue volume/wall volume x (100%) is presented as percentage. Annualized change presented mm^3/year (for volume) and as percentage change/year." (NCT00715273)
Timeframe: Measured at Years 1, 2, and 3
| Intervention | percentage change/year (Mean) | |
|---|---|---|
| LRNC change | Wall Volume change | |
| 1 - Single Therapy Group | -1.6 | -0.6 |
| 2 - Double Therapy Group | -3.6 | -1.4 |
| 3 - Triple Therapy Group | -2.8 | -1.2 |
Any cardiovascular events such as death from any cause, nonfatal myocardial infarction, stroke, and revascularization procedures (PCI or CABG) due to unstable ischemia will be recorded and verified. (NCT00715273)
Timeframe: Measured at Years 3, 4, and 5
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Composite Measured at Year 3 | Composite Measured at Year 4 (cumulative) | Composite Measured at Year 5 (cumulative) | |
| 1 - Single Therapy Group | 6 | 7 | 9 |
| 2 - Double Therapy Group | 6 | 11 | 11 |
| 3 - Triple Therapy Group | 7 | 9 | 9 |
The change in the coefficient of variation (CV) of continuous glucose readings, as assessed by Continuous Glucose Monitoring (CGM) (NCT01524705)
Timeframe: At baseline, 6 months of intervention
| Intervention | percentage (Mean) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | -2.43 |
| Insulin Glargine, Metformin, Prandial Insulin | 0.44 |
% of glycosylated hemoglobin in whole blood at 26 weeks (NCT01524705)
Timeframe: Baseline vs 26 weeks
| Intervention | % of HbA1C (Mean) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | 7.1 |
| Insulin Glargine, Metformin, Prandial Insulin | 7.2 |
Severe hypoglycemia-documented glucose <50mg/dl (participant journal), and hypoglycemic attacks requiring hospitalization, or treatment by emergency personnel. (NCT01524705)
Timeframe: 26 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | 0 |
| Insulin Glargine, Metformin, Prandial Insulin | 0 |
Weight in kg at 26 weeks minus weight at baseline. (NCT01524705)
Timeframe: Baseline vs 26 weeks
| Intervention | kg (Mean) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | -4.8 |
| Insulin Glargine, Metformin, Prandial Insulin | 0.7 |
(NCT00120289)
Timeframe: Time to first event measured from date of randomization through last follow-up visit (common termination), for an average of 36 months follow-up, maximum 66 months.
| Intervention | participants (Number) |
|---|---|
| ERN + Simvastatin | 45 |
| Placebo + Simvastatin | 38 |
(NCT00120289)
Timeframe: Time to first event measured from date of randomization through last follow-up visit (common termination) for an average of 36 months follow-up, maximum 66 months.
| Intervention | participants (Number) |
|---|---|
| ERN + Simvastatin | 282 |
| Placebo + Simvastatin | 274 |
(NCT00120289)
Timeframe: Time to first event measured from date of randomization through last follow-up visit (common termination) for an average of 36 months follow-up, maximum 66 months
| Intervention | participants (Number) |
|---|---|
| ERN + Simvastatin | 171 |
| Placebo + Simvastatin | 158 |
(NCT00120289)
Timeframe: Time to first event measured from date of randomization through last follow-up visit (common termination) for an average of 36 months follow-up, maximum 66 months
| Intervention | participants (Number) |
|---|---|
| ERN + Simvastatin | 156 |
| Placebo + Simvastatin | 138 |
32 reviews available for niacin and Arteriosclerosis, Coronary
| Article | Year |
|---|---|
Lipid-Lowering Agents in Older Individuals: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Coronary Artery Disease; Diabetes Mellitus; Fibric | 2019 |
HDL quality or cholesterol cargo: what really matters--spotlight on sphingosine-1-phosphate-rich HDL.
Topics: Animals; Atherosclerosis; Cardiotonic Agents; Cholesterol, HDL; Coronary Artery Disease; Drug Therap | 2013 |
Effectiveness of combination therapy with statin and another lipid-modifying agent compared with intensified statin monotherapy: a systematic review.
Topics: Anticholesteremic Agents; Azetidines; Bile Acids and Salts; Cholesterol, LDL; Coronary Artery Diseas | 2014 |
Niacin and progression of CKD.
Topics: Comorbidity; Coronary Artery Disease; Disease Progression; Endothelium, Vascular; Humans; Hypolipide | 2015 |
LDL reduction: how low should we go and is it safe?
Topics: Allylamine; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Colesevelam Hydrochloride; Coron | 2008 |
Cardiovascular therapies and associated glucose homeostasis: implications across the dysglycemia continuum.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2009 |
Nicotinic acid and the prevention of coronary artery disease.
Topics: Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Coronary Artery Disease; Humans; Niaci | 2009 |
Novel targets that affect high-density lipoprotein metabolism: the next frontier.
Topics: Apolipoprotein A-I; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Clinical Trials as Topic; | 2009 |
Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease.
Topics: Cardiovascular Diseases; Coronary Artery Disease; Humans; Hypolipidemic Agents; Myocardial Infarctio | 2010 |
High-density lipoprotein and coronary heart disease: current and future therapies.
Topics: Acetyl-CoA C-Acetyltransferase; Animals; Apolipoprotein A-I; Biological Transport; Cholesterol Ester | 2010 |
Genetic determinants of plasma triglycerides.
Topics: Adaptor Proteins, Signal Transducing; Angiopoietin-Like Protein 3; Angiopoietin-like Proteins; Angio | 2011 |
[Hypertricglyceridemia: prognostic impact and treatment options].
Topics: Adult; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Diet, R | 2011 |
Niacin and statin combination therapy for atherosclerosis regression and prevention of cardiovascular disease events: reconciling the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Ou
Topics: Aged; Cardiovascular Diseases; Coronary Artery Disease; Drug Therapy, Combination; Female; Follow-Up | 2012 |
Niacin: a powerful adjunct to other lipid-lowering drugs in reducing plaque progression and acute coronary events.
Topics: Acute Disease; Algorithms; Clinical Trials as Topic; Coronary Artery Disease; Coronary Disease; Diab | 2003 |
HDL: the metabolism, function, and therapeutic importance.
Topics: Animals; Anticholesteremic Agents; Apolipoprotein A-I; ATP-Binding Cassette Transporters; Carrier Pr | 2004 |
Treating low HDL--from bench to bedside.
Topics: Animals; Cholesterol; Coronary Artery Disease; Coronary Disease; Endothelium, Vascular; Humans; Hype | 2004 |
Have we forgotten the pivotal role of high-density lipoprotein cholesterol in atherosclerosis prevention?
Topics: Arteriosclerosis; Cholesterol, HDL; Clofibric Acid; Coronary Artery Disease; Disease Progression; Hu | 2005 |
Commentary: A new approach to atherogenic dyslipidemia.
Topics: Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Humans; Hyperlipidemias; Hypolipidemic | 2005 |
Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks.
Topics: Allylamine; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Clinical Trials as | 2005 |
Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Topics: Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diet; Drug T | 2005 |
To statin or to non-statin in coronary disease--considering absolute risk is the answer.
Topics: Acute Coronary Syndrome; Aspirin; Atherosclerosis; Cholesterol, LDL; Coronary Artery Disease; Diet; | 2007 |
Hypertriglyceridemia: its etiology, effects and treatment.
Topics: Clofibric Acid; Coronary Artery Disease; Diet; Exercise; Humans; Hydroxymethylglutaryl-CoA Reductase | 2007 |
High-density lipoprotein metabolism: potential therapeutic targets.
Topics: Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Coronary Artery Disease; Humans; Hydroxymethylgl | 2007 |
Reducing the residual risk of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor therapy with combination therapy.
Topics: Anticholesteremic Agents; C-Reactive Protein; Cholesterol, HDL; Coronary Artery Disease; Drug Therap | 2008 |
Evidence to support aggressive management of high-density lipoprotein cholesterol: implications of recent imaging trials.
Topics: Anticholesteremic Agents; Cholesterol, HDL; Clofibric Acid; Coronary Artery Disease; Disease Progres | 2008 |
Number-needed-to-treat analysis of the prevention of myocardial infarction and death by antidyslipidemic therapy.
Topics: Coronary Angiography; Coronary Artery Disease; Disease Progression; Female; Humans; Hydroxymethylglu | 1996 |
Perspectives in the treatment of dyslipidemias in the prevention of coronary heart disease.
Topics: Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Combined Modality Therapy; Coronary Artery Disease; | 1998 |
Lipid altering or antioxidant vitamins for patients with coronary disease and very low HDL cholesterol? The HDL-Atherosclerosis Treatment Study Design.
Topics: Adult; Aged; Antioxidants; Cholesterol, HDL; Coronary Angiography; Coronary Artery Disease; Coronary | 1998 |
The antiatherogenic role of high-density lipoprotein cholesterol.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Animals; Anticholesteremic Agents; Aryldialkylphosph | 1998 |
Effect of niacin on atherosclerotic cardiovascular disease.
Topics: Cerebrovascular Disorders; Coronary Artery Disease; Drug Therapy, Combination; Humans; Hypolipidemic | 1998 |
A risk factor for atherosclerosis: triglyceride-rich lipoproteins.
Topics: Coronary Artery Disease; Diabetes Mellitus; Drug Therapy, Combination; Gemfibrozil; Humans; Hydroxym | 2001 |
Current approaches to drug therapy for the hypercholesterolemic patient.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Coronary Artery Disease; Humans; Hydroxymethylglutaryl-C | 1989 |
27 trials available for niacin and Arteriosclerosis, Coronary
| Article | Year |
|---|---|
Effect of Extended-Release Niacin on Carotid Intima Media Thickness, Reactive Hyperemia, and Endothelial Progenitor Cell Mobilization: Insights From the Atherosclerosis Lesion Progression Intervention Using Niacin Extended Release in Saphenous Vein Grafts
Topics: Aged; Atherosclerosis; Carotid Arteries; Carotid Intima-Media Thickness; Coronary Artery Disease; De | 2015 |
Relationship of baseline HDL subclasses, small dense LDL and LDL triglyceride to cardiovascular events in the AIM-HIGH clinical trial.
Topics: Aged; Anticholesteremic Agents; Cardiovascular Diseases; Cardiovascular System; Cholesterol, HDL; Co | 2016 |
Effects of oral niacin on endothelial dysfunction in patients with coronary artery disease: results of the randomized, double-blind, placebo-controlled INEF study.
Topics: Administration, Oral; Aged; Biomarkers; Blood Glucose; Brachial Artery; Cell Adhesion Molecules; Cho | 2009 |
Combined use of extended-release niacin and atorvastatin: safety and effects on lipid modification.
Topics: Aged; Anticholesteremic Agents; Apolipoproteins A; Atorvastatin; Cholesterol; Cholesterol, HDL; Chol | 2009 |
Impact of increases in high-density lipoprotein cholesterol on cardiovascular outcomes during the armed forces regression study.
Topics: Adult; Aged; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, HDL; Cholestyramine Res | 2010 |
The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study partici
Topics: Aged; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Coronary Arte | 2011 |
[Pleiotropic effects of nicotinic acid therapy in men with coronary heart disease and elevated lipoprotein(a) levels].
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Atherosclerosis; Atorvastatin; Carotid Arteries; Cor | 2011 |
Niacin improves lipid profile but not endothelial function in patients with coronary artery disease on high dose statin therapy.
Topics: Aged; Atorvastatin; Coronary Artery Disease; Endothelium, Vascular; Female; Heptanoic Acids; Humans; | 2013 |
Impact of simvastatin, niacin, and/or antioxidants on cholesterol metabolism in CAD patients with low HDL.
Topics: Antioxidants; Cholesterol; Constriction, Pathologic; Coronary Artery Disease; Desmosterol; Drug Ther | 2003 |
Comparison of effectiveness of statin monotherapy versus statin and niacin combination therapy in primary prevention and effects on calcified plaque burden.
Topics: Anti-Infective Agents; Coronary Artery Disease; Drug Therapy, Combination; Female; Fluoroquinolones; | 2003 |
Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study).
Topics: Blood Glucose; Cholesterol, HDL; Coronary Artery Disease; Double-Blind Method; Drug Therapy, Combina | 2004 |
Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Biomarkers; C-Reactive Protein; Cholesterol, HDL; Co | 2006 |
Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients. Harvard Atherosclerosis Reversibility Project (HARP) Group.
Topics: Anticholesteremic Agents; Cardiac Catheterization; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; | 1994 |
Progression of coronary artery disease predicts clinical coronary events. Long-term follow-up from the Cholesterol Lowering Atherosclerosis Study.
Topics: Adult; Colestipol; Coronary Angiography; Coronary Artery Disease; Diet, Fat-Restricted; Follow-Up St | 1996 |
Progression of coronary artery disease predicts clinical coronary events. Long-term follow-up from the Cholesterol Lowering Atherosclerosis Study.
Topics: Adult; Colestipol; Coronary Angiography; Coronary Artery Disease; Diet, Fat-Restricted; Follow-Up St | 1996 |
Progression of coronary artery disease predicts clinical coronary events. Long-term follow-up from the Cholesterol Lowering Atherosclerosis Study.
Topics: Adult; Colestipol; Coronary Angiography; Coronary Artery Disease; Diet, Fat-Restricted; Follow-Up St | 1996 |
Progression of coronary artery disease predicts clinical coronary events. Long-term follow-up from the Cholesterol Lowering Atherosclerosis Study.
Topics: Adult; Colestipol; Coronary Angiography; Coronary Artery Disease; Diet, Fat-Restricted; Follow-Up St | 1996 |
Progression of coronary artery disease predicts clinical coronary events. Long-term follow-up from the Cholesterol Lowering Atherosclerosis Study.
Topics: Adult; Colestipol; Coronary Angiography; Coronary Artery Disease; Diet, Fat-Restricted; Follow-Up St | 1996 |
Progression of coronary artery disease predicts clinical coronary events. Long-term follow-up from the Cholesterol Lowering Atherosclerosis Study.
Topics: Adult; Colestipol; Coronary Angiography; Coronary Artery Disease; Diet, Fat-Restricted; Follow-Up St | 1996 |
Progression of coronary artery disease predicts clinical coronary events. Long-term follow-up from the Cholesterol Lowering Atherosclerosis Study.
Topics: Adult; Colestipol; Coronary Angiography; Coronary Artery Disease; Diet, Fat-Restricted; Follow-Up St | 1996 |
Progression of coronary artery disease predicts clinical coronary events. Long-term follow-up from the Cholesterol Lowering Atherosclerosis Study.
Topics: Adult; Colestipol; Coronary Angiography; Coronary Artery Disease; Diet, Fat-Restricted; Follow-Up St | 1996 |
Progression of coronary artery disease predicts clinical coronary events. Long-term follow-up from the Cholesterol Lowering Atherosclerosis Study.
Topics: Adult; Colestipol; Coronary Angiography; Coronary Artery Disease; Diet, Fat-Restricted; Follow-Up St | 1996 |
Lipid altering or antioxidant vitamins for patients with coronary disease and very low HDL cholesterol? The HDL-Atherosclerosis Treatment Study Design.
Topics: Adult; Aged; Antioxidants; Cholesterol, HDL; Coronary Angiography; Coronary Artery Disease; Coronary | 1998 |
Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density.
Topics: Aged; Anticholesteremic Agents; Apolipoproteins B; Centrifugation, Density Gradient; Chemical Phenom | 1999 |
Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density.
Topics: Aged; Anticholesteremic Agents; Apolipoproteins B; Centrifugation, Density Gradient; Chemical Phenom | 1999 |
Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density.
Topics: Aged; Anticholesteremic Agents; Apolipoproteins B; Centrifugation, Density Gradient; Chemical Phenom | 1999 |
Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density.
Topics: Aged; Anticholesteremic Agents; Apolipoproteins B; Centrifugation, Density Gradient; Chemical Phenom | 1999 |
Serial quantitative coronary angiography and coronary events.
Topics: Adult; Cholesterol, LDL; Colestipol; Collateral Circulation; Coronary Angiography; Coronary Artery D | 2000 |
Correlations between measures of atherosclerosis change using carotid ultrasonography and coronary angiography.
Topics: Adult; Carotid Artery, Common; Carotid Stenosis; Colestipol; Coronary Angiography; Coronary Artery D | 2000 |
Beneficial effects of pravastatin (+/-colestyramine/niacin) initiated immediately after a coronary event (the randomized Lipid-Coronary Artery Disease [L-CAD] Study).
Topics: Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Chemopreven | 2000 |
Low-dose, time-release nicotinic acid: effects in selected patients with low concentrations of high-density lipoprotein cholesterol.
Topics: Cholesterol, HDL; Coronary Artery Disease; Delayed-Action Preparations; Female; Humans; Male; Middle | 1992 |
Comparison of computer- and human-derived coronary angiographic end-point measures for controlled therapy trials.
Topics: Adult; Colestipol; Combined Modality Therapy; Computers; Coronary Angiography; Coronary Artery Disea | 1992 |
Effect of lovastatin or niacin combined with colestipol and regression of coronary atherosclerosis.
Topics: Apolipoprotein A-I; Apolipoproteins B; Cholesterol, HDL; Cholesterol, LDL; Colestipol; Coronary Angi | 1992 |
[Angiographic regression of coronary atheromatosis].
Topics: Angiography; Anticholesteremic Agents; Coronary Angiography; Coronary Artery Disease; Drug Therapy, | 1991 |
Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens.
Topics: Adult; Aged; Cholesterol, HDL; Cholesterol, LDL; Colestipol; Coronary Artery Disease; Drug Therapy, | 1990 |
Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up.
Topics: Adult; Apolipoproteins; Cholesterol; Colestipol; Coronary Artery Disease; Drug Therapy, Combination; | 1990 |
Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up.
Topics: Adult; Apolipoproteins; Cholesterol; Colestipol; Coronary Artery Disease; Drug Therapy, Combination; | 1990 |
Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up.
Topics: Adult; Apolipoproteins; Cholesterol; Colestipol; Coronary Artery Disease; Drug Therapy, Combination; | 1990 |
Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up.
Topics: Adult; Apolipoproteins; Cholesterol; Colestipol; Coronary Artery Disease; Drug Therapy, Combination; | 1990 |
Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts. Lipid and nonlipid factors.
Topics: Apolipoprotein C-III; Apolipoproteins; Apolipoproteins C; Colestipol; Coronary Angiography; Coronary | 1990 |
Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts.
Topics: Adult; Clinical Trials as Topic; Colestipol; Coronary Artery Bypass; Coronary Artery Disease; Drug T | 1987 |
Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts.
Topics: Adult; Clinical Trials as Topic; Colestipol; Coronary Artery Bypass; Coronary Artery Disease; Drug T | 1987 |
Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts.
Topics: Adult; Clinical Trials as Topic; Colestipol; Coronary Artery Bypass; Coronary Artery Disease; Drug T | 1987 |
Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts.
Topics: Adult; Clinical Trials as Topic; Colestipol; Coronary Artery Bypass; Coronary Artery Disease; Drug T | 1987 |
43 other studies available for niacin and Arteriosclerosis, Coronary
| Article | Year |
|---|---|
Evidence Supporting Niacin Therapy Is More Nuanced Than Article States.
Topics: Coronary Artery Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agent | 2018 |
Stabilization of atherosclerotic plaques: an update.
Topics: Antihypertensive Agents; Apolipoprotein B-100; Blood Platelets; CCR5 Receptor Antagonists; Chemokine | 2013 |
Effects of Rosuvastatin Versus Atorvastatin, Alone or in Combination, on Lipoprotein (a).
Topics: Apolipoprotein A-I; Atorvastatin; Cholesterol; Coronary Artery Disease; Drug Therapy, Combination; F | 2016 |
To statin or to non-statin in coronary disease-considering absolute risk is the answer.
Topics: Acute Coronary Syndrome; Atherosclerosis; Cholesterol, LDL; Coronary Artery Disease; Diet; Fatty Aci | 2008 |
What can I do to lower my lipoprotein(a) level?
Topics: Cholesterol, LDL; Coronary Artery Disease; Humans; Hypolipidemic Agents; Lipoprotein(a); Niacin; Ris | 2008 |
Combined statin and niacin therapy remodels the high-density lipoprotein proteome.
Topics: Adult; Aged; Amino Acid Sequence; Coronary Artery Disease; Drug Therapy, Combination; Humans; Hydrox | 2008 |
Combined statin and niacin therapy remodels the high-density lipoprotein proteome.
Topics: Adult; Aged; Amino Acid Sequence; Coronary Artery Disease; Drug Therapy, Combination; Humans; Hydrox | 2008 |
Combined statin and niacin therapy remodels the high-density lipoprotein proteome.
Topics: Adult; Aged; Amino Acid Sequence; Coronary Artery Disease; Drug Therapy, Combination; Humans; Hydrox | 2008 |
Combined statin and niacin therapy remodels the high-density lipoprotein proteome.
Topics: Adult; Aged; Amino Acid Sequence; Coronary Artery Disease; Drug Therapy, Combination; Humans; Hydrox | 2008 |
Commentary to factors predicting cardiovascular events in statin-treated diabetic and non-diabetic patients with coronary atherosclerosis.
Topics: Cholesterol, LDL; Clinical Trials as Topic; Coronary Artery Disease; Diabetes Complications; Diabete | 2010 |
Trial clouds use of niacin with a statin.
Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Clinical Trials as | 2011 |
Therapy and clinical trials.
Topics: Amides; Cholesterol Ester Transfer Proteins; Coronary Artery Disease; Diabetes Mellitus; Drug Therap | 2011 |
Is niacin ineffective? Or did AIM-HIGH miss its target?
Topics: Brain Ischemia; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Dyslipidemias; Female; | 2012 |
High patient compliance with nicacin/laropiprant in large clinical trial: interim safety and tolerability results from HPS-2 THRIVE study released at 2012 ESC congress: drug trends in cardiology.
Topics: Chemical Safety; China; Cholesterol, HDL; Coronary Artery Disease; Europe; Follow-Up Studies; Humans | 2012 |
Targeting specific traditional risk factors to improve cardiovascular outcomes: Sound or flawed?
Topics: Atorvastatin; Coronary Artery Disease; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydro | 2013 |
Effectiveness of aggressive management of dyslipidemia in a collaborative-care practice model.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Cohort Studies; Coop | 2003 |
Advances in the understanding and management of dyslipidemia: using niacin-based therapies.
Topics: Chemistry, Pharmaceutical; Cholesterol, HDL; Coronary Artery Disease; Delayed-Action Preparations; D | 2003 |
Nicotinic acid in the treatment of ischaemic heart-disease.
Topics: Coronary Artery Disease; Coronary Disease; Myocardial Ischemia; Niacin; Nicotinic Acids | 1960 |
[The use of nicotinic acid in patients with coronary insufficiency].
Topics: Cardiotonic Agents; Coronary Artery Disease; Coronary Disease; Niacin; Nicotinic Acids | 1961 |
[PROLONGED TREATMENT WITH LARGE DOSES OF NICOTINIC ACID IN CORONARY ARTERIOSCLEROSIS].
Topics: Coronary Artery Disease; Coronary Disease; Humans; Hyperlipidemias; Niacin; Nicotinic Acids | 1964 |
[ON THE THERAPY OF CORONARY INSUFFICIENCY].
Topics: Anticoagulants; Coronary Artery Disease; Coronary Disease; Digitalis Glycosides; Dipyridamole; Drug | 1964 |
Relation of response of subclinical atherosclerosis detected by electron beam tomography to baseline low-density lipoprotein cholesterol levels.
Topics: Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; | 2004 |
[Use of nicotinic acid in coronary insufficiency].
Topics: Coronary Artery Disease; Coronary Vessels; Humans; Niacin; Nicotinic Acids | 1950 |
Assessment of compliance with lipid guidelines in an academic medical center.
Topics: Academic Medical Centers; American Heart Association; Angioplasty, Balloon, Coronary; Cerebrovascula | 2006 |
"Flush-free niacin": dietary supplement may be "benefit-free".
Topics: Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Dietary Supplements; Flushing; Humans; | 2006 |
[Safety and tolerability of nicotinic acid. Results of the multicenter, open, prospective NAUTILUS study].
Topics: Adverse Drug Reaction Reporting Systems; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LD | 2006 |
Treating hypertriglyceridemia.
Topics: Adult; Clofibric Acid; Coronary Artery Disease; Diet; Exercise; Heparin; Humans; Hydroxymethylglutar | 2007 |
Treating hypertriglyceridemia.
Topics: Clofibric Acid; Coronary Artery Disease; Diet; Exercise; Humans; Hydroxymethylglutaryl-CoA Reductase | 2007 |
Treating hypertriglyceridemia.
Topics: Clofibric Acid; Coronary Artery Disease; Diet; Exercise; Fatty Acids, Omega-3; Humans; Hydroxymethyl | 2007 |
Niacin therapy: an evolving paradigm for the management of mixed dyslipidemia and low high-density lipoprotein cholesterol. Introduction.
Topics: Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Dyslipidemias; Humans; Hypolipidemic Ag | 2008 |
Influence of xantinole nicotinic acid on cutaneous microcirculation in patients with coronary artery disease and hyperlipoproteinemia.
Topics: Aged; Blood Pressure; Capillaries; Coronary Artery Disease; Female; Heart Rate; Humans; Hyperlipopro | 2008 |
Use of neural networks in predicting the risk of coronary artery disease.
Topics: Adult; Cholesterol; Colestipol; Coronary Artery Disease; Coronary Disease; Diet, Fat-Restricted; Fol | 1995 |
Elevated lipoprotein (a) blood levels as the single treatable atherosclerotic risk factor in patients with coronary artery disease.
Topics: Aged; Coronary Artery Disease; Humans; Lipoprotein(a); Male; Middle Aged; Niacin; Risk Factors | 1993 |
[The effect of long-term Enduracin monotherapy on the clinical and biochemical status of patients with ischemic heart disease].
Topics: Adult; Cardiovascular System; Coronary Artery Disease; Delayed-Action Preparations; Digestive System | 1997 |
Antioxidants blunt high-density lipoprotein response to statin plus niacin therapy.
Topics: Antioxidants; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Clinical Trials as Topic; Coron | 2001 |
Myocardial glucose utilization and optimization of (18)F-FDG PET imaging in patients with non-insulin-dependent diabetes mellitus, coronary artery disease, and left ventricular dysfunction.
Topics: Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Fluorodeoxyglucose F18; Glucose; Glucose | 2001 |
Niacin-simvastatin combination benefits patients with coronary artery disease.
Topics: Antioxidants; Coronary Artery Disease; Drug Therapy, Combination; Humans; Hypolipidemic Agents; Niac | 2001 |
Lipid-lowering drug use and cardiovascular events after myocardial infarction.
Topics: Cholesterol; Clofibrate; Cohort Studies; Coronary Artery Disease; Coronary Disease; Female; Humans; | 2002 |
The effects of simvastatin-niacin and antioxidant therapy on HDL.
Topics: Antioxidants; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Drug Therapy, Combination | 2002 |
Multiple Methods for Reduction of Lipoprotein(a).
Topics: Ascorbic Acid; Carnitine; Coronary Artery Disease; Diet, Reducing; Estrogens; Exercise; Female; Huma | 2002 |
A novel mechanism for the beneficial vascular effects of high-density lipoprotein cholesterol: enhanced vasorelaxation and increased endothelial nitric oxide synthase expression.
Topics: Case-Control Studies; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Endothelium, Vasc | 2002 |
Evaluation of colestipol/niacin therapy with computer-derived coronary end point measures. A comparison of different measures of treatment effect.
Topics: Adult; Colestipol; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; Coronary V | 1992 |
[Antilipemic agents and postprandial lipidemia].
Topics: Cholesterol; Chylomicrons; Coronary Artery Disease; Dietary Fats; Diterpenes; Female; Fenofibrate; H | 1990 |
The effects of nicotinic acid treatment on high density lipoprotein particle size subclass levels in hyperlipidaemic subjects.
Topics: Adult; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Dose-Response Relationship, Drug | 1990 |
Colestipol-niacin therapy and coronary atherosclerosis.
Topics: Adult; Colestipol; Coronary Artery Disease; Humans; Male; Middle Aged; Niacin; Polyamines; Research | 1987 |
[Blood plasma prostanoids in coronary atherosclerosis patients].
Topics: Adult; Aged; Coronary Artery Disease; Drug Evaluation; Female; Hemoperfusion; Humans; Male; Middle A | 1986 |